US 12,268,674 B2
Mi-2β inhibitor as an immunotherapy agent
Hong-yu Li, Little Rock, AR (US); Zhengyu Wang, Little Rock, AR (US); Jingwei Shao, Little Rock, AR (US); and Rutao Cui, Hangzhou (CN)
Assigned to BioVentures, LLC, Little Rock, AR (US)
Filed by BioVentures, LLC, Little Rock, AR (US)
Filed on Mar. 16, 2022, as Appl. No. 17/696,610.
Claims priority of provisional application 63/161,651, filed on Mar. 16, 2021.
Prior Publication US 2022/0304990 A1, Sep. 29, 2022
Int. Cl. A61K 31/437 (2006.01); A61K 31/4725 (2006.01); A61K 31/497 (2006.01); A61K 45/06 (2006.01); C07D 471/04 (2006.01); C07D 519/00 (2006.01)
CPC A61K 31/437 (2013.01) [A61K 31/4725 (2013.01); A61K 31/497 (2013.01); A61K 45/06 (2013.01); C07D 471/04 (2013.01); C07D 519/00 (2013.01)] 18 Claims
OG exemplary drawing
 
1. A method for treating a cancer in a subject comprising administering an effective amount of a Mi-2β inhibitor to the subject, wherein the effective amount of the Mi-2β inhibitor is co-administered with an immunotherapy, and wherein the cancer is resistant to the immunotherapy in the absence of the effective amount of the Mi-2β inhibitor, and
wherein the Mi-2β inhibitor is a compound of formula

OG Complex Work Unit Chemistry
wherein—
Ring 1 is

OG Complex Work Unit Chemistry
Ring 2 is

OG Complex Work Unit Chemistry
R4 is hydrogen, a halo, or an unsubstituted or substituted, unbranched or branched, saturated or unsaturated C1-C6 alkyl;
each X and Y are independently selected from N or CH;
R1 is hydrogen;
each R2 is independently selected from hydrogen, an unsubstituted or substituted, unbranched or branched, saturated or unsaturated C1-C6 alkyl, an unsubstituted or substituted, unbranched or branched, saturated or unsaturated C1-C6 alkylaryl, an aryl, or -L2-A;
L1 and L2 are independently selected from the group consisting of alkylenyl, heteroalkylenyl, and —((CH2)m—W—(CH2)n)p-;
W is selected from the group consisting of —O—, —N(R2)—, —C(═O) N(R2—N(R2)C(═O)—, —C═C—, and —C═C— or W is absent;
m is 0, 1, 2, 3, 4, 5, 6, 7, or 8;
n is 0, 1, 2, 3, 4, 5, 6, 7, or 8;
p is 0, 1, 2, or 3;
A is selected from the group consisting of:

OG Complex Work Unit Chemistry
B1, B2, B3, and B4 are independently selected from the group consisting of —C(R3)═ and —N═;
R3 is selected from the group consisting of hydrogen, deuterium, methyl, and fluoro; and
Z1 is selected from the group consisting of —CH2, —C(═O)—, and —N═C(CH3)— wherein the nitrogen atom of —N═C(CH3)— is attached to the hexatomic ring.